Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMRN | Amarin Corporation Plc Sponsored ADR | 0.16% | 18.42 | 1.8% | $132.46m | |
| ICPT | Intercept Pharmaceuticals, Inc. | 4.05% | 90.53 | 18.6% | $94.99m | |
| SAGE | SAGE Therapeutics, Inc. | 0.89% | 166.98 | 8.8% | $82.15m | |
| JAZZ | Jazz Pharmaceuticals Plc | 3.03% | 129.78 | 2.3% | $71.68m | |
| GWPH | GW Pharmaceuticals PLC Sponsored ADR | 2.21% | 165.56 | 6.3% | $60.71m | |
| PRGO | Perrigo Co. Plc | 0.38% | 49.75 | 6.8% | $54.82m | |
| ZGNX | Zogenix, Inc. | 0.48% | 37.39 | 9.9% | $45.65m | |
| UTHR | United Therapeutics Corporation | 5.53% | 104.31 | 14.3% | $44.47m | |
| CTLT | Catalent Inc | 0.91% | 44.44 | 2.4% | $39.76m | |
| HZNP | Horizon Pharma plc | 2.98% | 25.26 | 6.7% | $35.55m | |
| PTLA | Portola Pharmaceuticals, Inc. | 2.76% | 35.40 | 7.6% | $33.06m | |
| ICLR | ICON Plc | 3.89% | 135.05 | 4.1% | $30.66m | |
| ZYNE | Zynerba Pharmaceuticals Inc | 4.21% | 9.90 | 8.3% | $28.70m | |
| MYOK | MyoKardia, Inc. | 2.06% | 49.07 | 2.4% | $25.77m | |
| MNK | Mallinckrodt Plc | 3.15% | 18.36 | 21.0% | $25.24m |
Company Profile
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.